Adults taking the novel once-daily oral pill for plaque psoriasis had significantly higher rates of clear or almost clear ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

A potential rally to 6,000 is possible if retail sales are positive and the FOMC Meeting is dovish. Read why investors should ...

The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...

Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...

Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...

Bristol Myers Squibb gets European Commission approval to expand use of CAR T cell therapy, Breyanzi for relapsed or refractory follicular lymphoma: Princeton, New Jersey Monday, ...

Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.

The European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...